Anti-Stathmin Antibody [PD00-54]
HA721179
ApplicationsFlow Cytometry, ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetSTMN1
Overview
- SupplierHUABIO
- Product NameAnti-Stathmin Antibody [PD00-54]
- Delivery Days Customer2
- ApplicationsFlow Cytometry, ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDPD00-54
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID3925
- Target nameSTMN1
- Target descriptionstathmin 1
- Target synonymsC1orf215, LAP18, Lag, OP18, PP17, PP19, PR22, SMN, stathmin, leukemia-associated phosphoprotein p18, metablastin, oncoprotein 18, phosphoprotein 19, phosphoprotein p19, prosolin, stathmin 1/oncoprotein 18, testicular tissue protein Li 189, transmembrane protein C1orf215
- HostRabbit
- IsotypeIgG
- Protein IDP13668
- Protein NameStathmin
- Scientific DescriptionStathmin, also known as oncoprotein 18 (Op18), is a ubiquitously expressed 19 kDa cytosolic phosphoprotein responsible for integrating various cellular regulatory signals. Stathmin has been implicated in both G1-S and G2-M checkpoint control of cell cycle progression and plays a major role in cell proliferation, differentiation, development and morphogenesis. Overexpression of Stathmin has been associated with tumor progression in endometrial carcinomas, ovarian carcinoma and oral squamous cell carcinoma. A recent study by Howitt et al. on 193 cervical lesions demonstrated that Stathmin was positive in 5/56 (9%) CIN1, 5/11 (45%) CIN2, 14/15 (93%) CIN3 cases of cervical intraepithelial neoplasias; and all of adenocarcinoma in situ (19/19), invasive squamous cell carcinoma (32/32) and adenocarcinoma (34/34) cases. It is valuable to distinguish CIN3 from the majority of low-grade precursors and negative/reactive cervical biopsies.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC41116161